



This week in therapeutics

This week in the apeutics				
Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hepatic disea	se			
Liver disease	Proteasome activator subunit 3 (PSME3)	Mouse studies suggest inhibition of the proteasome activator PSME3 could help treat and prevent liver steatosis. In mice fed a high-fat diet, deletion of <i>Psme3</i> prevented lipid accumulation and onset of liver steatosis. Next steps include analyzing the effects of <i>Psme3</i> loss in other mouse models of obesity. SciBX 6(39); doi:10.1038/scibx.2013.1098 Published online Oct. 10, 2013	Unpatented; licensing status not applicable	Dong, S. et al. Cell Metab; published online Sept. 3, 2013; doi:10.1016/j.cmet.2013.08.012 Contact: Chuangui Wang, Institute of Biomedical Sciences, Shanghai, China e-mail: cgwang@bio.ednu.edu.cn Contact: Xiaotao Li, same affiliation as above e-mail: xiaotaol@bcm.edu